Astrazeneca (AZN) EPS (Basic) Growth (3y) (2012 - 2026)
Astrazeneca (AZN) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -34.06% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -35.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.68% |
| Mar 31, 2026 | -10.99% |
| Dec 31, 2025 | -6.86% |
| Sep 30, 2025 | 16.20% |
| Jun 30, 2025 | 104.74% |
| Mar 31, 2025 | 108.58% |
| Dec 31, 2024 | 56.55% |
| Sep 30, 2024 | 46.33% |
| Jun 30, 2024 | 11.14% |
| Mar 31, 2024 | 20.81% |
| Dec 31, 2023 | 0.46% |
| Sep 30, 2023 | 2.28% |
| Jun 30, 2023 | 21.69% |
| Mar 31, 2023 | 46.60% |
| Dec 31, 2022 | 31.78% |
| Sep 30, 2022 | 82.99% |
| Jun 30, 2022 | 8.80% |
| Mar 31, 2022 | -15.18% |
| Sep 30, 2021 | -98.36% |
| Jun 30, 2021 | 61.80% |